Transcelline Competitors

“LAXAI is a global Functional Service Provider of Drug R & D and Clinical Research services that enable biopharmaceutical companies to drive drugs to market cost effectively and efficiently” We offer the below services: CLINICAL RESEARCH • Biostatistics & SAS Programming • Clinical Data Management • Clinical Operations • Medical Writing • CDISC Consulting • Pharmacovigilance & Drug Safety Reporting DRUG DISCOVERY • Medicinal Chemistry • Targeted Library Synthesis • Custom Synthesis • Process Development & Scale-up • Analytical Services

PharmTech is the authoritative source for practical applications and expert analyses for scientists, engineers, and managers engaged in process development, manufacturing, formulation and drug delivery, API synthesis, analytical technology and testing, packaging, IT, outsourcing, and regulatory compliance in the pharmaceutical and biotechnology industries.

Quality Systems Compliance LLC serves the needs of businesses working in the ISO and FDA GMP Regulated Industries including Medical Devices, Pharmaceuticals, Tissues, Quality Systems Compliance LLC can help you achieve and maintain quality compliance, while meeting deadlines and containing costs. If you plan and implement your quality system correctly, it doesn't have to be expensive to be in a state of compliance. In fact, implementing your quality system correctly the first time can reduce risk and liability. We can help your company plan, implement, and maintain a compliant quality system. Quality Systems Compliance LLC provides auditing support including GAP ASSESSMENTS, INTERNAL AUDITS, SUPPLIER AUDITS, and DUE DILIGENCE AUDITS. Quality Systems Compliance LLC offers training in quality systems, quality control, assurance, and quality compliance. Additionally, courses are available in statistics, process validation, Design of Experiments (DOE), Gage R&R and Measurement System Analysis (MSA). Quality Systems Compliance LLC can provide support before, during, and after ISO and FDA Inspections including 483 and Warning Letter responses.